Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
Clinical trial NCT06245824 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06245824
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-30
- Primary completion
- 2026-03-01
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.